Elderly Kidney Transplant Recipient With Intermittent Fever: A Case Report of Leishmaniasis With Acute Kidney Injury During Liposomal Amphotericin B Therapy

Pedroso, José Alberto Rodrigues; Salerno, Maria Paola; Spagnoletti, Gionata; Zoccali, Marco; Zaccone, G.; Bianchi, Valentina; Romagnoli, Jacopo; Citterio, Franco

doi:10.1016/j.transproceed.2014.07.064

Cited by 9 publications

(23 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Information regarding the country of origin or travel activity was available for 153/159 (96.2%) patients. The vast majority ( n = 143) of KT recipients with Leishmaniasis came from or had travelled to endemic regions, especially South America, North Africa, the Middle East, India, or the Mediterranean basin [ 4 , 16 , 17 , 18 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 30 , 31 , 34 , 35 , 36 , 38 , 40 , 41 , 42 , 44 , 45 , 48 , 50 , 51 , 52 , 54 , 55 , 56 , 57 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 69 , 70 , 71 , 72 , 73 , 75 , 76 , 78 , 79 , 81 …”

Section: Resultsmentioning

confidence: 99%

“…Most episodes of Leishmania infection were registered in Brazil ( n = 66) [ 22 , 29 , 30 , 40 , 58 , 68 , 74 , 79 ]. Several cases were also reported in the Mediterranean basin ( n = 61), such as Spain ( n = 20) [ 18 , 27 , 36 , 41 , 48 , 53 , 55 , 61 , 63 , 68 , 78 ], Italy ( n = 14) [ 31 , 33 , 35 , 42 , 44 , 45 , 51 , 72 , 81 ], France ( n = 10) [ 25 , 39 , 64 ], Tunisia ( n = 8) [ 7 , 17 , 34 , 52 , 62 , 69 ], Greece ( n = 4) [ 54 ], Turkey ( n = 3) [ 59 , 67 , 77 ], Malta ( n = 1) [ 38 ], and Algeria ( n = 1) [ 23 ]. Overall, European countries outside the Mediterranean basin recorded a small number of infections: Portugal ( n = 2) [ 24 , 66 ], Switzerland ( n ...…”

Section: Resultsmentioning

confidence: 99%

“…Patients’ age ranged from 12 to 76 years, with a single pediatric case [ 23 ] and 18 recipients older than 60 years [ 10 , 17 , 31 , 33 , 35 , 47 , 58 , 63 , 64 , 66 , 70 , 72 , 73 , 75 , 81 ]. In the study by Alves da Silva et al [ 22 ] enrolling 20 patients, the mean age at diagnosis was 37 (±10.7) years.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Epidemiology, Clinical Characteristics, Diagnostic Work Up, and Treatment Options of Leishmania Infection in Kidney Transplant Recipients: A Systematic Review

Favi

Santolamazza²,

Botticelli³

et al. 2022

TropicalMed

View full text Add to dashboard Cite

Current knowledge on Leishmania infection after kidney transplantation (KT) is limited. In order to offer a comprehensive guide for the management of post-transplant Leishmaniasis, we performed a systematic review following the latest PRISMA Checklist and using PubMed, Scopus, and Embase as databases. No time restrictions were applied, including all English-edited articles on Leishmaniasis in KT recipients. Selected items were assessed for methodological quality using a modified Newcastle–Ottawa Scale. Given the nature and quality of the studies (case reports and retrospective uncontrolled case series), data could not be meta-analyzed. A descriptive summary was therefore provided. Eventually, we selected 70 studies, describing a total of 159 cases of Leishmaniasis. Most of the patients were adult, male, and Caucasian. Furthermore, they were frequently living or travelling to endemic regions. The onset of the disease was variable, but more often in the late transplant course. The clinical features were basically similar to those reported in the general population. However, a generalized delay in diagnosis and treatment could be detected. Bone marrow aspiration was the preferred diagnostic modality. The main treatment options included pentavalent antimonial and liposomal amphotericin B, both showing mixed results. Overall, the outcomes appeared as concerning, with several patients dying or losing their transplant.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology, Clinical Characteristics, Diagnostic Work Up, and Treatment Options of Leishmania Infection in Kidney Transplant Recipients: A Systematic Review

Favi

Santolamazza²,

Botticelli³

et al. 2022

TropicalMed

View full text Add to dashboard Cite

show abstract

“…One case, after duplicate, was removed, and 36 cases were excluded according to exclusion criteria i (out of scope) and iv (insufficient available data). In the present review we only analyzed cases regarding SOT recipients published from 1996 to 2016 and available on the PubMed database with sufficient data for inclusion on synthesis of results (n 907) [ 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , ...…”

Section: Resultsmentioning

confidence: 99%

“…Leishmaniasis is a vector-borne tissue parasitic disease, localized (cutaneous and muco-cutaneous) or systemic (visceral leishmaniasis = VL), caused by the kinetoplastidae Leishmania genus. Cases are recorded among patients undergoing kidney, liver, heart, lung and pancreas transplantation, with the most significant association with kidney transplantation (84.1%, based on the 127 cases reported in the literature) [ 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 ]. VL is the most frequently observed clinical presentation, followed by mucosal and more rarely, cutaneous.…”

Section: Discussionmentioning

confidence: 99%

Solid Organ Transplant and Parasitic Diseases: A Review of the Clinical Cases in the Last Two Decades

2018

View full text Add to dashboard Cite

The aim of this study was to evaluate the occurrence of parasitic infections in solid organ transplant (SOT) recipients. We conducted a systematic review of literature records on post-transplant parasitic infections, published from 1996 to 2016 and available on PubMed database, focusing only on parasitic infections acquired after SOT. The methods and findings of the present review have been presented based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) checklist. From data published in the literature, the real burden of parasitic infections among SOT recipients cannot really be estimated. Nevertheless, publications on the matter are on the increase, probably due to more than one reason: (i) the increasing number of patients transplanted and then treated with immunosuppressive agents; (ii) the “population shift” resulting from immigration and travels to endemic areas, and (iii) the increased attention directed to diagnosis/notification/publication of cases. Considering parasitic infections as emerging and potentially serious in their evolution, additional strategies for the prevention, careful screening and follow-up, with a high level of awareness, identification, and pre-emptive therapy are needed in transplant recipients.

show abstract

Leishmaniasis in Transplant Candidates and Recipients: Diagnosis and Management

Clemente¹,

Mourão²

2020

Emerging Transplant Infections

View full text Add to dashboard Cite

Leishmaniasis is a rare disease in both solid-organ and hematopoietic stem cell transplantation. Additionally, the frequency of disease is likely related to the leishmaniasis prevalence in the general population. Although cutaneous leishmaniasis (CL) presentation is more prevalent than that of visceral leishmaniasis (VL) in the general population, the opposite occurs in transplant patients. The current available knowledge is based on small series, case reports, or extrapolations from studies conducted in the general population or in immunocompromised subjects. Therefore, recommendations for disease management are based on the opinion of experts. Leishmania transmission through organ grafts has not been conclusively demonstrated, and there are relatively low rates of transfusion-transmitted leishmaniasis (TTL). To date, compulsory screening for VL in organ donors and the deferral criteria have still not been established. In the context of transplant recipients, diagnosis and management remain a challenge. Delayed diagnosis frequently occurs because of low clinical suspicion and atypical disease presentation. Liposomal amphotericin is the drug of choice and the most commonly used therapy. However, patient profile, Leishmania species, disease extent, drug availability or toxicity, presence of concomitant infections, and especially response can influence this choice. Immunosuppression dose reduction is often recommended, but such decisions must be taken on an individual basis. The main challenges include donor screening and organ deferral, duration of therapy, secondary prophylaxis, and follow-up.

show abstract

Elderly Kidney Transplant Recipient With Intermittent Fever: A Case Report of Leishmaniasis With Acute Kidney Injury During Liposomal Amphotericin B Therapy

Cited by 9 publications

References 9 publications

Epidemiology, Clinical Characteristics, Diagnostic Work Up, and Treatment Options of Leishmania Infection in Kidney Transplant Recipients: A Systematic Review

Epidemiology, Clinical Characteristics, Diagnostic Work Up, and Treatment Options of Leishmania Infection in Kidney Transplant Recipients: A Systematic Review

Solid Organ Transplant and Parasitic Diseases: A Review of the Clinical Cases in the Last Two Decades

Leishmaniasis in Transplant Candidates and Recipients: Diagnosis and Management

Contact Info

Product

Resources

About